October 2021

Ushering the New Era in Anti-Drug Antibody Assays with Next Generation Protein Sequencing

2021-10-15T13:30:54-04:00October 15th, 2021|Whitepapers|

Anti-drug antibody (ADA) assays are critical to assess the clinical efficacy and safety of a biological drug and rely on control reagents that mimic the ADA response to the biological drug being tested. These positive controls typically consist of animal-derived pooled polyclonal antibodies or human monoclonal antibody reference panels against the target protein drug.

September 2021

De Novo Protein Sequencing

2021-10-05T08:01:38-04:00September 28th, 2021|Webinars|

Abstract In this on-demand webinar, we briefly cover the fundamentals of protein sequencing, how researchers have benefited from implementing protein sequencing into their pipelines, and discuss how Rapid Novor is able to routinely and robustly achieve 100% accuracy and 100% coverage for both monoclonal and oligoclonal antibodies. Webinar details [...]

August 2021

What are Monoclonal Antibodies?

2021-10-12T13:04:45-04:00August 25th, 2021|Articles|

Monoclonal antibodies (mAbs) are homogenous antibodies that bind to a single epitope on an antigen. Kohler and Milstein generated the first mAbs when they developed hybridoma technology in the 1970s. Because of the specificity, homogeneity and unlimited availability, mAbs are valuable reagents used in a variety of important applications including treatment and diagnosis of diseases

July 2021

June 2021

Bispecific Therapeutics Explained

2021-10-12T13:27:42-04:00June 28th, 2021|Articles|

Bispecific therapeutics are monoclonal antibodies that carry a specific antigen-binding capability on each arm. Bispecifics are thus capable of having two specificities that can either double the binding affinity of the antibody toward the same antigen (increased avidity), or can now bind to two targets. Bispecifics are most often described as two types: trispecifics and bispecific T-cell engaged antibodies (BiTE).

March 2021

The Underlying Cause of Medical Diagnostic Invalidation

2021-10-14T12:30:50-04:00March 23rd, 2021|Whitepapers|

In vitro diagnostics (IVDs) are one of the most commonly used tools to diagnose conditions and guide treatment decisions, and are often considered the “silent champion” of healthcare. They work by detecting the absence or presence of particular markers or by measuring the concentration of analytes or specific substances.

September 2020

Leveraging Recombinant Patient Antibodies in Therapeutic Applications

2021-10-04T16:39:20-04:00September 3rd, 2020|Webinars|

Leveraging Recombinant Patient Antibodies in Therapeutic Applications Originally presented at PEGS Boston Virtual 2020 by Anthony Stajduhar, Director of International Business Development, Rapid Novor Our team has perfected the art of monoclonal antibody sequencing, and is now ready to demonstrate our ability to sequence mAbs from polyclonal mixtures. In this talk, Anthony [...]